TGTX · TG Therapeutics, Inc.

Operating leverage emerged strongly, with income from operations reaching $34.8 million (303.6% YoY growth, 17.0% margin), as revenue growth outpaced SG&A expansion linked to commercialization ramp and modest stock-based compensation increases from higher headcount and grant-date stock prices (Item 3). Net income followed at $19.8 million (290.8% YoY), delivering diluted EPS of $0.12 versus $0.03, underscoring the transition to sustained profitability after historical losses (Item 3 Liquidity and Capital Resources). These results affirm strategic focus on neurological and immunological fields, though management notes risks if execution falters (Item 1A Risk Factors).

Forward, revenue estimates incorporate contractual requirements, customer mix, pricing changes, and government calculations, with government purchase volumes inherently uncertain (Item 3, Item 1A). Reliance on sole-source manufacturing partners introduces supply risks (Item 1A), and compliance costs could elevate expenses. Yet Q1 execution—profitable operations, cash discipline, and return of capital—positions TG Therapeutics to navigate fluctuations while scaling BRIUMVI globally.